A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

Phase I Trial of a CD8+T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis

“…The vaccine comprised the HLA B*0801-restricted CD8 ϩ T-cell epitope FLRGRAYGL (FLR) from the latent antigen EBNA3 (9, 10) and tetanus toxoid (TT) as a source of CD4 ϩ T-cell help formulated in the water-in-oil adjuvant, Montanide ISA 720. This adjuvant has been successfully used to induce peptide-epitope-specific CD8 ϩ T-cell responses in mice (20,48) and has been used in several human vaccine trials (23,36,46,62).…”

Safety and skin delayed-type hypersensitivity response in vervet monkeys immunized with Leishmania donovani sonicate antigen delivered with adjuvants

“…Following initial immunization, daily observation of immunized animals was carried out and we did not observe any local or systemic side effects in any of the animals immunized with MPLA+Ag or MISA+Ag. The safety of MISA has been reported elsewhere including in vaccination studies carried out in our laboratory (TOLEDO et al, 2001;MASINA et al, 2003;OLIVEIRA et al, 2005). Our safety report on MISA as an adjuvant for Leishmania vaccine differs from other studies that have associated this adjuvant with adverse reactions including swelling and erythema at the injection site observed within a few days following vaccination (PIERCE et al, 2010).…”

Development of Vaccine Adjuvants: A Historical Perspective

“…The Montanide ISA adjuvants (utilizing mineral oil and mannide monooleate, which emulsifi es water with a low energy input) [211] have a substantial record in veterinary applications. More recently, the ISA 720 formulation using vegetable oil has been tested in clinical trials with HIV peptide [212] and a malaria-HBV core antigen [213].…”